Exicure (XCUR) Non Operating Income (2016 - 2026)
Exicure (XCUR) reported Non Operating Income of -$188000.0 for Q1 2026, down 316.09% on a YoY basis from $87000.0 in Q1 2025, and up 26.27% quarter-over-quarter from -$255000.0 in Q4 2025.
Exicure (XCUR) Non Operating Income (2016 - 2026) Analysis & Trends
Exicure has reported Non Operating Income for 11 years, with the latest figure at -$188000.0 in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income fell 316.09% year-over-year to -$188000.0; the trailing twelve-month figure through Mar 2026 stood at -$601000.0 (down 122.9% YoY), and the FY2025 full-year result was -$275000.0, down 110.83% from the prior year.
- Non Operating Income for Q1 2026 stood at -$188000.0, up from -$255000.0 in the prior quarter.
- The five-year high for Non Operating Income was $1.9 million in Q4 2023, with the low at -$611000.0 in Q1 2022.
- Historically, Non Operating Income has averaged $230941.2 across 5 years, with a median of $44000.0 in 2023.
- Annual changes were most pronounced in 2023 — Non Operating Income plunged 2950.0% — and 2024, when it surged 3309.09%.
- Exicure's Non Operating Income stood at $513000.0 in 2022, then soared by 275.63% to $1.9 million in 2023, then plunged by 79.14% to $402000.0 in 2024, then tumbled by 163.43% to -$255000.0 in 2025, then rose by 26.27% to -$188000.0 in 2026.
- The last three Non Operating Income figures came in at -$188000.0 (Q1 2026), -$255000.0 (Q4 2025), and -$46000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 444,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 9.35 Mn |
| 10 | Exicure | 19.38 Mn | 16.77 Mn | - | -188,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -188,000.00 |
| Dec 31, 2025 | -255,000.00 |
| Sep 30, 2025 | -46,000.00 |
| Jun 30, 2025 | -112,000.00 |
| Mar 31, 2025 | 87,000.00 |
| Dec 31, 2024 | 402,000.00 |
| Sep 30, 2024 | 1.50 Mn |
| Jun 30, 2024 | 635,000.00 |
| Mar 31, 2024 | 7,000.00 |
| Dec 31, 2023 | 1.93 Mn |
| Sep 30, 2023 | 44,000.00 |
| Jun 30, 2023 | -122,000.00 |
| Mar 31, 2023 | 104,000.00 |
| Dec 31, 2022 | 513,000.00 |
| Sep 30, 2022 | 45,000.00 |
| Jun 30, 2022 | -4,000.00 |
| Mar 31, 2022 | -611,000.00 |
| Dec 31, 2021 | 1.17 Mn |
| Sep 30, 2021 | -5,000.00 |
| Jun 30, 2021 | -2,000.00 |